Kamil Ali-Jackson is CLO at Aclaris Therapeutics, Inc. (ACRS). They have made 11 open-market trades across 2 companies since 2016, most recently 2026-06-22.
CIK 0001654337
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $100K since 2021, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RIGL | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $35.00 | $88K | +15.1% | -0.5% | +32.1% |
| RIGL | SELL · 10b5-1 | 2026-05-26 | 2026-05-28 | $29.17 | $73K | -0.0% | +27.3% | +51.4% |
| PDSB | BUY | 2021-06-15 | 2021-06-17 | $8.50 | $100K | +12.5% | -8.3% | +47.0% |
| ACRS | SELL | 2021-06-03 | 2021-06-04 | $21.96 | $417K | -16.9% | -22.0% | -18.7% |
| ACRS | SELL | 2021-06-01 | 2021-06-02 | $22.10 | $2.0M | -18.1% | -21.6% | -25.6% |
| ACRS | SELL | 2021-05-06 | 2021-05-07 | $23.43 | $907K | +1.1% | -1.5% | -35.0% |
| ACRS | SELL | 2021-05-03 | 2021-05-05 | $24.08 | $2.1M | -9.1% | -8.8% | -37.4% |
| ACRS | SELL | 2018-06-11 | 2018-06-12 | $20.00 | $100K | -4.1% | +1.1% | -25.3% |
| ACRS | SELL | 2018-05-18 | 2018-05-21 | $20.00 | $200K | -4.1% | +6.8% | -15.9% |
| ACRS | SELL | 2016-10-26 | 2016-10-28 | $21.83 | $85K | +5.0% | +30.8% | +26.2% |
| ACRS | SELL | 2016-10-26 | 2016-10-28 | $21.83 | $85K | +5.0% | +30.8% | +26.2% |
| ACRS | SELL · 10b5-1 | 2016-09-28 | 2016-09-28 | $24.66 | $45K | -2.5% | -16.7% | +7.8% |
| ACRS | SELL | 2016-08-26 | 2016-08-29 | $20.35 | $76K | -3.5% | +13.5% | +25.9% |
| ACRS | SELL | 2016-08-26 | 2016-08-29 | $20.35 | $76K | -3.5% | +13.5% | +25.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.